Glucagon-Like Peptide-1 (Active) Mouse/Rat ELISA

Summary

GLP-1 is a peptide hormone from the intestinal mucosa, which is produced from its precursor, proglucagon by post transnational processing. GLP-1 may play a role in the physiological control of feeding. GLP-1 amide was supposed to improved glycemic control in patients with type 2 diabetes by increasing insulin secretion, by inhibiting glucagon secretion and by delaying gastric emptying rather than by altering extrapancreatic glucose metabolism. Intravenous GLP-1 and amide could normalize fasting hyperglycaemia in type 2 diabetic patients. Hyperglycaemia during parenteral nutrition could be controlled by exogenous GLP-1, whereas the chronic therapy of type 2 diabetes required GLP-1 derivatives with longer duration of action.

Features

• This is intended for research use only.
• Rapid assay (total reaction time: 5 hours).
• This kit is for GLP-1(7–36) amide in mouse/rat serum, plasma, culture medium and tissue extract.
• Assay format is 96 wells.
• Recombinant GLP-1(7–36) amide is used as the standard preparation.
• Components of the kit are provided ready to use or in concentrated form.

Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation

Notice

For sample collection we recommend using vacutainers containing EDTA and DPP4 inhibitor.

Assay format

Sandwich ELISA, Biotin-labelled antibody

Applications

Plasma, Serum

Sample requirements

10 µl/well

Storage/Shipping

When the complete kit is stored at 2–8 °C, the kit is stable until the expiration date shown on the label on the box. Opened reagents should be used as soon as possible to avoid less than optimal assay performance caused by storage environment.

Calibration Curve

Calibration range

1.56 – 50 pg/ml

Limit of detection

0.8 pg/ml

References to this product

• Matsui Y, Hirasawa Y, Sugiura T, Toyoshi T, Kyuki K, Ito M. Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. Biol Pharm Bull. 2010;33 (6):963-70
• Ohara-Imaizumi M, Aoyagi K, Akimoto Y, Nakamichi Y, Nishiwaki C, Kawakami H, Nagamatsu S. Imaging exocytosis of single glucagon-like peptide-1 containing granules in a murine enteroendocrine cell line with total internal reflection fluorescent microscopy. Biochem Biophys Res Commun. 2009 Dec 4;390 (1):16-20

References to summary

• Asarian L, Corp ES, Hrupka B, Geary N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol Behav. 1998 Jun 1;64 (3):367-72
• Habener JF, Gros P, Heinrich G. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. J Biol Chem. 1984 Nov 25;259 (22):14082-7
• Habener JF, Kopczynski MG, Mojsov S. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990 May 15;265 (14):8001-8
• Hellstrom PM, Gutniak M, Holst JJ, Adner N, Mansten S, King N, Naslund E. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004 Mar;91 (3):439-46
• Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005 Jan;11 (1):90-4
• Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002 Nov-Dec;18 (6):430-41
• Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994 Apr;43 (4):535-9
• Schmiegel W, Holst JJ, Orskov C, Richter S, Bach I, Weber I, Nauck MA. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998 Nov;15 (11):937-45
• Schmiegel W, Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004 Apr 15;118 (1-2):89-97
• Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000 Apr;49 (4):611-7
• Yanaihara N. [Recent advances in gastrointestinal hormones]. Hum Cell. 1990 Mar;3 (1):1-8

By research topic:

• Diabetology - Other Relevant Products
• Energy metabolism and body weight regulation

By molecule:

• Glucagon-Like Peptide-1